Evaluation of a decision aid and a personal risk profile in community pharmacy for patients considering options to improve cardiovascular health: The OPTIONS pilot study

International Journal of Pharmacy Practice

Volumn 14, Issue 1, 2006, Pages 51-62

  Lalonde, Lyne ^a,b,c   O'Connor, Annette M ^c   Duguay, Pierrette ^d   Brassard, Joëlle ^b   Drake, Elizabeth ^c   Grover, Steven A ^d,e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Centre de Sante et de Services Sociaux de Laval   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d Division of Clinical Epidemiology

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BEHAVIOR CHANGE; BODY MASS; CANADA; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFLICT; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION AID; DECISION MAKING; DYSLIPIDEMIA; EVALUATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; KNOWLEDGE; LIFESTYLE; MALE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT EDUCATION; PATIENT SATISFACTION; PERCEPTION; PERSONAL RISK PROFILE; PHARMACIST ATTITUDE; PHARMACY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM;

EID: 33644608614     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1211/ijpp.14.1.0007     Document Type: Article

References (37)

1. Laboratory Centre for Disease Control, Health Canada, Statistics Canada, Canadian Institute for Health Information, Canadian Cardiovascular Society, Canadian Stroke Society et al. The changing face of heart disease and stroke in Canada 2000. Ottawa: Heart and Stroke Foundation of Canada; 1999.
2. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
3. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 1998;279:1458-62.
4. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11.
5. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
6. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 2003;169:921-4.
7. Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 2000;74 (suppl. 1):S23-8.
8. van Dam M, van Wissen S, Kastelein JJ. Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol. J Cardiovasc Risk 2002;9:89-95.
9. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
10. Joffres MR, Hamet P, MacLean DR, L'Italien G J, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001;14:1099-105.
11. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-102.
12. Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can J Public Health 1998;89:I16-I18.
13. Wagner EH, Groves T. Care for chronic diseases. BMJ 2002;325:913-4.
14. Bodenheimer T, Long K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA 2002;288:2469-75.
15. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002;288:1775-9.
16. Lewis R, Dixon J. Rethinking management of chronic diseases. BMJ 2004;328:220-2.
17. Schreurs KM, Colland VT, Kuijer RG, de Ridder DT, van Elderen T. Development, content, and process evaluation of a short self-management intervention in patients with chronic diseases requiring self-care behaviours. Pat Educ Couns 2003;51:133-41.
18. Holman H, Lorig K. Patients as partners in managing chronic disease. Partnership is a prerequisite for effective and efficient health care. BMJ 2000;320:526-7.
19. O'Connor AM, Rostom A, Fiset V et al. Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ 1999;319:731-4.
20. O'Connor AM, Tugwell P, Wells GA et al. Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Mak 1998;18:295-303.
21. Ottawa Health Research Institute. Patient decision aids. www.ohri.ca/programs/clinical_epidemiology/OPDSL/default. asp (accessed October 28, 2005).
22. O'Connor AM, Stacey D, Entwistle V et al. Decision aid for people facing health treatment or screening decisions (Cochrane Review). The Cochrane Library Issue 2. Oxford: Update Software; 2003
23. Lalonde L, O'Connor AM, Drake E, Duguay P, Lowensteyn I, Grover SA. Development and pre-testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular disease. Pharmacotherapy 2004;24:909-22.
24. Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover S. Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS). Prev Med 1998;27:730-7.
25. Ottawa Health Research Institute. Patient decision aids. www.ohri.ca/decisionaid (accessed October 28, 2005).
26. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995;310:975-8.
27. The Montreal Cardiovascular Health Improvement Program. www.chiprehab.com (accessed October 28, 2005).
28. Barry MJ. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med 2002;136:127-35.
29. Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. Can Med Assoc J 2000;162:1441-7.
30. O'Connor AM. Validation of a decisional conflict scale. Med Decis Mak 1995;15:25-30.
31. O'Connor AM. Decisional conflict scale. 1999. http://decision-aid.ohri. ca/eval.html (accessed October 31, 2005)
32. Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Physiother Theory Pract 1982;19:276-88.
33. Prochaska JO. Strong and weak principles for progressing from precontemplation to action on the basis of twelve problem behaviors. Health Psychol 1994;13:47-51.
34. Tsuyuki RT, Johnson JA, Teo KK et al. Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacother 1999;33:910-19.
35. Tsuyuki RT, Johnson JA, Teo KK et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162: 1149-55.
36. Ali F, Laurin MY, Lariviere C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol 2003;10:101-6.
37. O'Connor AM, Stacey D, Entwistle V et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2003;2:CD001431.